218 results on '"Krueger, James G."'
Search Results
2. Staphylococcus Aureus and Streptococcus Pyogenes Induce Psoriasis-Related Transcriptomes Augmented by IL-17A and TNF-α
3. A systematic review and critical appraisal of pharmacological treatments for pediatric hidradenitis suppurativa
4. Cathelicidin Antimicrobial Peptide LL37 Induces Toll-Like Receptor 8 and Amplifies IL-36γ and IL-17C in Human Keratinocytes
5. Proteomic characterization of atopic dermatitis blood from infancy to adulthood
6. Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial
7. Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis
8. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
9. Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy
10. Skin proteomic analysis of immune activation associated with regression of melanoma metastases induced by diphencyprone
11. 33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
12. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
13. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis
14. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement
15. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris
16. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
17. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression
18. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets
19. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients
20. Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis
21. In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes
22. IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response in Human Keratinocytes
23. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults
24. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa
25. Cardiovascular Risk in Patients With Psoriasis
26. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities
27. Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis
28. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
29. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation
30. Tape-strips provide a minimally invasive approach to track therapeutic response to topical corticosteroids in atopic dermatitis patients
31. 15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis
32. 14928 Epithelialized tracts are active mediators of inflammation in hidradenitis suppurativa
33. 17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab
34. 15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis
35. Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design
36. A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis
37. Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures
38. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study
39. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
40. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis
41. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data
42. Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept
43. Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy
44. Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients
45. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature
46. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis
47. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis
48. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
49. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
50. Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.